Non-hodgkin Lymphoma,B Cell Clinical Trial
Official title:
The Efficacy and Safety of Lenalidomide With or Without Rituximab and Other Drugs in B-cell Non-Hodgkin Lymphomas: a Real-world Study.
Describe the treatment of B-cell non-Hodgkin lymphoma patients who receive lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs), and evaluate the efficacy and safety of lenalidomide single drug or lenalidomide combined with rituximab (with or without other drugs) in the real-world setting.
This is a multi-center prospective, observational real-world study, targeting patients with
B-cell non-Hodgkin's lymphomas. This study is designed to evaluate the efficacy and safety of
lenalidomide single drug or lenalidomide combined with rituximab (with or without other
drugs) in the real-world setting.
This study will mainly focus on the following three cohorts:
Cohort 1: patients diagnosed with CD20-positive diffuse large B-cell lymphoma; Cohort 2:
patients diagnosed with CD20-positive follicle lymphoma; Cohort 3: patients on maintenance
treatment who have achieved complete remission or partial remission after induction therapy.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05050461 -
Immune Response After SARS-CoV-2 Vaccination in a Context of Non-Hodgkin Lymphoma
|
N/A | |
| Recruiting |
NCT06160362 -
The Safety and Efficacy of Double-target CART-19 and 20 Cells in Non-Hodgkin's Lymphoma (NHL)
|
N/A | |
| Recruiting |
NCT03720496 -
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With CD19-TriCART Cell Therapy
|
Phase 1 | |
| Recruiting |
NCT06346912 -
CD19-BAFF CAR-T Cells Therapy for Patients With Relapsed / Refractory B-cell ALL and B-cell NHL
|
Early Phase 1 | |
| Recruiting |
NCT05518383 -
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
|
Phase 4 | |
| Recruiting |
NCT02081937 -
CART-19 Immunotherapy in Mantle Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06321289 -
Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05909059 -
CAR T-cell Therapy in Patients With Renal Dysfunction
|
Phase 2 | |
| Recruiting |
NCT05631912 -
TRAC Locus-inserted CD19-targeting STAR-T Cell Therapy in r/r B-NHL
|
Phase 1/Phase 2 | |
| Completed |
NCT04094142 -
Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05143112 -
Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04661020 -
CD19 CAR-T Therapy for Patients With B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT03497533 -
Treatment of Refractory/Relapsed Non-Hodgkin Lymphoma With TriCAR-T_CD19
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04532268 -
A Study of Humanized CD19 CAR-T Cells Therapy for Patients With Relapsed and/or Refractory B-cell ALL and B-cell NHL
|
Early Phase 1 | |
| Terminated |
NCT03488251 -
PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05741359 -
The Safety and Efficacy of BRL-201 in the Treatment of r/r B Lymphocyte Non-Hodgkin Lymphoma
|
Phase 1 | |
| Recruiting |
NCT04897477 -
Azacytidine, Bendamustine, Piamprizumab in Refractory/Relapsed B-cell Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06156774 -
SARcopenia and Simplified Geriatric Assessment in Lymphoma Patients Undergoing CAR-T Cell Therapy: the FIL_SAR-CAR Project
|